Interpace Diagnostics Group, Inc. (IDXG)

1.4200 +0.0300 (+2.16%) At close: 10:21AM EDT

Interpace Diagnostics Group, Inc.

Waterview Plaza
Suite 310 2001 Route 46
Parsippany, NJ 07054
United States
855 776 6419
https://www.interpace.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 108

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Thomas W. Burnell Ph.D.	President, CEO & Chairman	634.17k	N/A	1963
Mr. Christopher McCarthy	Chief Financial Officer	N/A	N/A	1992
Dr. Sydney D. Finkelstein	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jody Campbell	Chief Revenue Officer	N/A	N/A	N/A
Dr. Nicole Massoll M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Patrick Kane	VP & Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Corporate governance

Interpace Diagnostics Group, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.